RxDoctor Payments Data

Chad Derosa, MD

Urology · Fort Carson, CONPI 1740471275

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $5,208 of the $7,581 with a category attached, or 68.7%. Procept Biorobotics Corporation accounts for 79.9% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2024 at $4,734 and has fallen 64.8% since, to $1,667 in 2025.

$7,581in general payments, 2019–2025

Across 57 payments — averaging $132.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$6K
  • Teleflex LLC$866
  • Urogen Pharma, Inc.$139
  • Boston Scientific$104
  • Sumitomo Pharma America, Inc.$96
  • Convatec Inc.$85
  • plus $232 from 7 others

What the payments were for

  • Travel & lodging$5,20869%
  • Food & beverage$2,31931%
  • Education$541%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,581 in reported general payments places this provider in the 75th percentile of 225 urology providers in Colorado.

See all urology providers in Colorado

Medicare billing

Part B allowed, 2024
$232,622
Medicare patients
489
Services billed
4,847

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron95$88,353
Trospium Chloride78$8,760
Tamsulosin Hcl552$7,324
Estradiol99$7,239
Methenamine Hippurate65$7,206
Finasteride339$5,276
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst117$4,211
Potassium Citrate ErPotassium Citrate20$3,725
Silodosin25$2,440
Oxybutynin Chloride ErOxybutynin Chloride58$1,581
Testosterone Cypionate32$1,316
Oxybutynin Chloride100$808
Alfuzosin Hcl ErAlfuzosin Hcl26$746
CefuroximeCefuroxime Axetil52$637
Imipramine Hcl28$509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$25$88,35395 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 225 urology providers in Colorado.

Other urology in Fort Carson

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →